Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentA combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samplesTargeting survival pathways in chronic myeloid leukaemia stem cellsHigh imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsSelection of therapy: rational decisions based on molecular events.Development of an effective therapy for chronic myelogenous leukemiaImatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.Immunological Analyses of Leukemia Stem Cells.Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.Are nilotinib-associated vascular adverse events an under-estimated problem?Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment.Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability.Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.An atomistic model for simulations of nilotinib and nilotinib/kinase binding
P2860
Q26766299-D46727EB-7FE0-4913-8151-D3998B7F0DBCQ36462972-BFF8C009-4AFB-4D84-9335-829DF4220859Q36622106-24DDBA91-3479-4A2D-BE84-6043D061C5CEQ36817650-D354D826-8105-482C-9086-58F2325C0D56Q37122686-E69D5095-EB9B-45E9-A63D-5CE94FC12315Q37381574-831F29C8-4338-424E-862E-9081C006AD36Q37952910-85D2EB58-843C-47D1-A694-BB0D99781B23Q37966917-B84B7C92-67AE-4CD1-8838-97DC0C90B0E1Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DBQ38825799-576E1702-A604-4E64-A640-7D973F4FC876Q38948507-5E1623AA-A857-4A59-900B-F9E97C3A6D34Q41530191-FA97E710-968F-4CEA-8677-483D6B912995Q41655434-0EFA79C1-3410-4756-AAA8-90F92E109694Q42407714-152959E7-DE42-4636-BBB9-4C3DEDA5A697Q45805301-B6953544-7E18-4242-8A57-CF2D72E3A644Q47787457-0F2FDADC-E957-41EF-80CA-56C4427E9B37Q51754351-8E821753-B3CD-4476-8DCE-5AB19000A4D9Q53357202-3D8D80F8-F1B3-47EF-8F8B-097165CA3655Q57920675-65FB9096-8DAB-4E58-AB8D-50A3960FA89E
P2860
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@en
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@nl
type
label
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@en
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@nl
prefLabel
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@en
Nilotinib is superior to imati ...... d leukemia: the ENESTnd study.
@nl
P2093
P2860
P356
P1476
Nilotinib is superior to imati ...... id leukemia: the ENESTnd study
@en
P2093
Francis J Giles
Francois-Xavier Mahon
Gianantonio Rosti
Juan-Luis Steegmann
Philipp le Coutre
Photis Beris
Richard E Clark
P2860
P304
P356
10.1586/EHM.10.61
P577
2010-11-09T00:00:00Z